ILIdit F. Liberty

Idit F. Liberty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Idit F. Liberty has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A tool for assessing changes in food preferences and health perceptions during nutritional interventions

    by Maya Bar Or, Nuphar Vinegrad, Sara Menashe Auman, Idit F Liberty, Tom Schonberg

    Understanding how nutritional interventions alter food evaluations may help clarify mechanisms of dietary behavior change; however, most studies focus on intake outcomes and rarely assess within-person changes in subjective food evaluation. We developed a brief, image-based rating tool that measures two core dimensions of food evaluation, liking and perceived healthiness, using standardized food images. The tool was piloted in adults with type 2 diabetes participating in a medically supervised intervention that included structured glucose monitoring and professional dietary guidance. Ratings were collected at baseline, post-monitoring, and follow-up. In line with the methodological aim of this study, we examined whether the tool demonstrates internal coherence, sensitivity to change, and external validity against expert ratings and physiological measures, and whether it can capture item-level patterns relevant to eating behavior. Results provide preliminary evidence that the tool is feasible, it is low-burden, and capable of detecting coherent relationships between food liking and health perceptions, including coordinated within-person changes over time and meaningful associations with external benchmarks. To support scalability and self-administration, we also developed an online smartphone-based demonstration version to exemplify the task structure and user experience. Overall, this pilot study suggests that a short, flexible rating task can serve as a practical measurement tool for tracking intervention-relevant changes in food evaluation and for informing the design of future nutritional interventions.

  • Open Access

    Circulating isomiRs May Be Superior Biomarkers Compared to Their Corresponding miRNAs: A Pilot Biomarker Study of Using isomiR-Ome to Detect Coronary Calcium-Based Cardiovascular Risk in Patients with NAFLD

    by Nataly Makarenkov, Uri Yoel, Yulia Haim, Yair Pincu, Nikhil S. Bhandarkar, Aryeh Shalev, Ilan Shelef, Idit F. Liberty, Gal Ben-Arie, David Yardeni, et al.

    Circulating miRNAs are increasingly being considered as biomarkers in various medical contexts, but the value of analyzing isomiRs (isoforms of canonical miRNA sequences) has not frequently been assessed. Here we hypothesize that an in-depth analysis of the full circulating miRNA landscape could identify specific isomiRs that are stronger biomarkers, compared to their corresponding miRNA, for identifying increased CV risk in patients with non-alcoholic fatty liver disease (NAFLD)—a clinical unmet need. Plasma miRNAs were sequenced with next-generation sequencing (NGS). Liver fat content was measured with magnetic-resonance spectrometry (MRS); CV risk was determined, beyond using traditional biomarkers, by a CT-based measurement of coronary artery calcium (CAC) score and the calculation of a CAC score-based CV-risk percentile (CAC-CV%). This pilot study included n = 13 patients, age > 45 years, with an MRS-measured liver fat content of ≥5% (wt/wt), and free of overt CVD. NGS identified 1103 miRNAs and 404,022 different isomiRs, of which 280 (25%) and 1418 (0.35%), respectively, passed an abundance threshold. Eighteen (sixteen/two) circulating miRNAs correlated positively/negatively, respectively, with CAC-CV%, nine of which also significantly discriminated between high/low CV risk through ROC-AUC analysis. IsomiR-ome analyses uncovered 67 isomiRs highly correlated (R ≥ 0.55) with CAC-CV%. Specific isomiRs of miRNAs 101-3p, 144-3p, 421, and 484 exhibited stronger associations with CAC-CV% compared to their corresponding miRNA. Additionally, while miRNAs 140-3p, 223-3p, 30e-5p, and 342-3p did not correlate with CAC-CV%, specific isomiRs with altered seed sequences exhibited a strong correlation with coronary atherosclerosis burden. Their predicted isomiRs-specific targets were uniquely enriched (compared to their canonical miRNA sequence) in CV Disease (CVD)-related pathways. Two of the isomiRs exhibited discriminative ROC-AUC, and another two showed a correlation with reverse cholesterol transport from cholesterol-loaded macrophages to ApoB-depleted plasma. In summary, we propose a pipeline for exploring circulating isomiR-ome as an approach to uncover novel and strong CVD biomarkers.


  • Open Access

    Simplifying carb counting: A randomized controlled study – Feasibility and efficacy of an individualized, simple, patient‐centred carb counting tool

    by Shulamit Witkow, Idit F. Liberty, Irina Goloub, Malka Kaminsky, Olga Otto, YonesAbu Rabia, Ilana Harman Boehm, Rachel Golan

    Introduction: The purpose of this study was to introduce and test a simple, individualized carbohydrate counting tool designed for persons with Type 1 Diabetes Mellitus (T1DM) in order to determine whether the tool improved A1C levels for participants with age, education or language barriers.Methods: In a randomized controlled trial, 85 participants were offered six diabetes instructional sessions free of charge over a six‐month period. Forty‐one received guidance using the regular carbohydrate counting (RCC) method. Forty‐four received guidance using an individualized ‘Simple Carb Counting’ (SCC), involving two customized tables prepared for participants.Results: The simple, individualized SCC tool for carbohydrate counting was non‐inferior to the standard method of RCC. The SCC tool was more effective among participants aged 40 and older, while no differences were found when comparing participants by education level. Irrespective of intervention group, all participants improved their A1C level (9.9% = 13.2 mmol/L vs 8.6% = 11.1 mmol/L, p = .001). A greater improvement in A1C level was seen in newly diagnosed participants (−6.1 vs −0.7, p = .005, −3.4 vs 0.9, p = .032) in both the RCC and SCC groups. All participants expressed improved emotional level per their PAID5 questionnaires (Problem Areas in Diabetes Scale‐PAID), (10.6 (±5.7) vs 9.5 (±5.7), p = .023), with women reporting greater improvement than men.Conclusions: SCC is a simple, individualized, feasible, low‐tech tool for carbohydrate counting, which promotes and enables accurate insulin dosing in people with T1DM. It was found more effective among participants aged 40 and older. Additional studies are needed to corroborate these findings.


  • Glycemic control and macular edema in patients undergoing cataract surgery

    by Amit Rachmilevich, Noam Yanculovich, Itai Hazan, Erez Tsumi, Idit F. Liberty


  • Open Access

    Visceral Adipose Tissue E2F1-miRNA206/210 Pathway Associates with Type 2 Diabetes in Humans with Extreme Obesity

    by Nitzan Maixner, Yulia Haim, Matthias Blüher, Vered Chalifa-Caspi, Isana Veksler-Lublinsky, Nataly Makarenkov, Uri Yoel, Nava Bashan, Idit F. Liberty, Ivan Kukeev, et al.

    Objective: Up-regulated expression of transcription-factor E2F1 in human visceral adipose tissue (VAT) characterizes a dysmetabolic obesity sub-phenotype. An E2F1-miRNA network has been described in multiple cancers. Here we investigated whether elevated VAT-E2F1 in obesity is associated with VAT-miRNA alterations similar to, or distinct from, those described in cancer. Furthermore, we assessed if E2F1-associated miRNA changes may contribute to the link between high- VAT-E2F1 and a dysmetabolic obesity phenotype. Methods: We assembled a cohort of patients with obesity and high-VAT-E2F1, matched by age, sex, ±BMI to patients with low-VAT-E2F1, with and without obesity (8 patients/groupX3 groups). We performed Nanostring©-based miRNA profiling of VAT samples from all 24 patients. Candidate E2F1-related miRNAs were validated by qPCR in an independent cohort of patients with extreme obesity, with or without type-2-diabetes (T2DM) (n = 20). Bioinformatic tools and manipulation of E2F1 expression in cells were used to establish the plausibility of the functional VAT-E2F1-miRNA network in obesity. Results: Among n = 798 identified miRNAs, 17 were differentially expressed in relation to E2F1 and not to obesity itself. No evidence for the cancer-related E2F1-miRNA network was identified in human VAT in obesity. In HEK293-cells, overexpression/downregulation of E2F1 correspondingly altered the expression of miRNA-206 and miRNA-210-5p, two miRNAs with reported metabolic functions consistent with those of E2F1. In VAT from both cohorts, the expression of both miRNA-206 and 210-5p intercorrelated, and correlated with the expression of E2F1. In cohort 1 we did not detect significant associations with biochemical parameters. In cohort 2 of patients with extreme obesity, all those with high VAT-E2F1 showed a diabetes-complicated obesity phenotype and higher expression of miRNA-206 and miRNA-210-5p, which also correlated with fasting glucose levels (both miRNAs) and fasting insulin (miRNA-210-5p). Conclusions: Whilst the previously described cancer-related E2F1-miRNA network does not appear to operate in VAT in obesity, miRNAs-206 and 210-5p may link high-E2F1 expression in VAT with diabetes-complicated extreme obesity phenotype.


  • Human adipose tissue is a putative direct target of daytime orexin with favorable metabolic effects: A cross‐sectional study

    by Nir Goldstein, Hiroshi Tsuneki, Nikhil Bhandarkar, Eleonora Aimaretti, Yulia Haim, Kanta Kon, Kiyofumi Sato, Tsutomu Wada, Idit F. Liberty, Boris Kirshtein, et al.

    Objective: Orexin/hypocretin (Ox) and its receptors (OxR), a neuroendocrine system centrally regulating sleep/wakefulness, were implicated in the regulation of peripheral metabolism. It was hypothesized that human adipose tissue constitutes a direct target of the OxA/OxR system that associates with distinct metabolic profile(s).Methods: Serum Ox levels and abdominal subcutaneous and visceral adipose tissue expression of Ox/HCRT, OxR1/HCRTR1, and OxR2/HCRTR2 were measured in n = 81 patients.Results: Higher morning circulating Ox levels were associated with improved lipid profile and insulin sensitivity, independently of BMI (β = −0.363, p = 0.018 for BMI‐adjusted homeostatic model of insulin resistance). Adipose HCRT mRNA was detectable in HCRT expressers were mostly (80%) males and, compared with nonexpressers, had lower total and LDL cholesterol. HCRTR1 was readily detectable, and HCRTR2 was undetectable. HCRTR1 mRNA and OxR1 protein expression were higher in subcutaneous than visceral adipose tissue, and among nonobese patients, patients with obesity, and patients with obesity and T2DM were 3.4 (1.0), 0.7 (0.1), 0.6 (0.1) (AU) (p < 0.001) and 1.0 (0.2), 0.5 (0.1), 0.4 (0.1) (AU) (p = NS), respectively. Higher visceral HCRTR1 expression was associated with lower fasting insulin and homeostatic model of insulin resistance, also after adjusting for BMI. In human adipocytes, HCRTR1 expression did not exhibit significant oscillation.Conclusions: Human adipose tissue is a putative direct target of the OxA‐OxR1 system, with higher morning input being associated with improved metabolic profile.


  • Open Access

    Higher Mast Cell Accumulation in Human Adipose Tissues Defines Clinically Favorable Obesity Sub-Phenotypes

    by Nir Goldstein, Yarden Kezerle, Yftach Gepner, Yulia Haim, Tal Pecht, Roi Gazit, Vera Polischuk, Idit F. Liberty, Boris Kirshtein, Ruthy Shaco-Levy, et al.

    The identification of human obesity sub-types may improve the clinical management of patients with obesity and uncover previously unrecognized obesity mechanisms. Here, we hypothesized that adipose tissue (AT) mast cells (MC) estimation could be a mark for human obesity sub-phenotyping beyond current clinical-based stratifications, both cross-sectionally and prospectively. We estimated MC accumulation using immunohistochemistry and gene expression in abdominal visceral AT (VAT) and subcutaneous (SAT) in a human cohort of 65 persons with obesity who underwent elective abdominal (mainly bariatric) surgery, and we validated key results in two clinically similar, independent cohorts (n = 33, n = 56). AT-MC were readily detectable by immunostaining for either c-kit or tryptase and by assessing the gene expression of KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), TPSB2 (tryptase beta 2), and CMA1 (chymase 1). Participants were characterized as VAT-MClow if the expression of both CMA1 and TPSB2 was below the median. Higher expressers of MC genes (MChigh) were metabolically healthier (lower fasting glucose and glycated hemoglobin, with higher pancreatic beta cell reserve (HOMA-β), and lower triglycerides and alkaline-phosphatase) than people with low expression (MClow). Prospectively, higher MC accumulation in VAT or SAT obtained during surgery predicted greater postoperative weight-loss response to bariatric surgery. Jointly, high AT-MC accumulation may be used to clinically define obesity sub-phenotypes, which are associated with a “healthier” cardiometabolic risk profile and a better weight-loss response to bariatric surgery.


  • Open Access

    Timing of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS

    by Idit F Liberty, Aviv Gelber, Lena Novack, Victor Novack, Esther Boteach, Ilana Harman‐Boehm

    The aim of this non‐randomised, pilot study was to examine the effect of insulin bolus injection timing on overall daily glucose control and glucose variability using a continuous glucose monitoring system (CGMS).Twelve patients with type 1 diabetes treated with either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), with HbA1c ≤7.5% (58mmol/mol), were connected twice to a CGMS for 72 hours. During period one the patients injected the insulin bolus before the meal and, during period two, after the meal. The variability of blood glucose (BG) was assessed by low BG indices (LBGI) and high BG indices (HBGI) – the measure of the variability of low and high BG readings. Their sum (LBGI + HBGI) gives the BG risk index (BGRI) – a measure of overall variability and deviations towards hypo‐ and hyperglycaemia.Six patients were on CSII and six on MDI. The number of meals, number of insulin injections and average BG were not different between the groups. LBGI and the number of hypoglycaemic events were not affected by the method of injection. BGRI were significantly higher for post‐meal injection, mainly due to increased hyperglycaemia (p=0.003). The increased HBGI and BGRI were more prominent in CSII (p=0.05). These differences were found for the 72‐hour variability but not when testing 2 hours post‐prandially.It was concluded that injecting insulin prior to the meal can reduce the overall glucose variability, and remains the preferred method of injection. Larger studies are needed in order to reinforce these results. Copyright © 2012 John Wiley & Sons.